Expanding the targets available to therapeutic antibodies via novel disease-specific markers

International Reviews of Immunology

Volumn 30, Issue 5-6, 2011, Pages 312-327

  Weidanz, Jon A ^a   Hildebrand, William H ^b  

^a Receptor Logic Inc   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

ADCC; cancer therapy; CDC; epitope discovery; Human Leukocyte Antigen (HLA); immunotherapy; infectious disease therapy; Major Histocompatibility Complex (MHC); mass spectrometry; monoclonal antibodies (mAbs); T cell receptor mimics (TCRms)

Indexed keywords

ANTIBODY; BEVACIZUMAB; CETUXIMAB; CYCLIN DEPENDENT KINASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; MARKER; NANOPARTICLE; PEPTIDE; PROGESTERONE RECEPTOR; PROTEOME; PROVENGE; RITUXIMAB; T LYMPHOCYTE RECEPTOR; TRASTUZUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; B LYMPHOCYTE; CANCER CELL; FEMALE; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOTHERAPY; INTRADUCTAL CARCINOMA; MALE; MASS SPECTROMETRY; MEDICAL DECISION MAKING; MELANOMA; NEOPLASM; NORMAL HUMAN; OVARY TUMOR; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TARGET CELL; WEST NILE FLAVIVIRUS;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CELL LINE, TUMOR; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY; MOLECULAR MIMICRY; NEOPLASMS; PEPTIDES; RECEPTORS, ANTIGEN, T-CELL;

EID: 80755188010     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2011.608136     Document Type: Article

References (24)

1. Wittman VP, et al. Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death. J Immunol. 2006;177(6):4187-4195. (Pubitemid 44359954)
2. Weidanz JA, et al. Levels of specific peptide-HLA class I complex predicts tumor cell susceptibility to CTL killing. J Immunol. 2006;177(8):5088-5097. (Pubitemid 44527579)
3. Weidanz JA, et al. Development and implementation of a direct detection, quantitation and validation system for class IMHC self-peptide epitopes. J Immunol Methods. 2007;318(1-2):47-58. (Pubitemid 46026805)
4. Cohen CJ, et al. Direct detection and quantitation of a distinct T-cell epitope derived from tumorspecific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Cancer Res. 2002;62(20):5835-5844. (Pubitemid 35204743)
5. Denkberg G, et al. Direct visualization of distinct T cell epitopes derived from a melanoma tumorassociated antigen by using human recombinant antibodieswithMHC- restricted T cell receptor-like specificity. Proc Natl Acad Sci U S A. 2002;99(14):9421-9426. (Pubitemid 34764629)
6. Andersen PS, et al. A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Proc Natl Acad Sci U S A. 1996;93(5):1820-1824. (Pubitemid 26079838)
7. Porgador A, et al. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity. 1997;6(6):715-726. (Pubitemid 27305734)
8. Nishida M, et al. Characterization of novelmurine anti-CD20monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab). Int J Oncol. 2007;31(1):29-40.
9. Vega MI, et al. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drugresistant B-NHL is independent of its Fc functions. Clin Cancer Res. 2009;15(21):6582-6594.
10. Carballido E, FishmanM. Sipuleucel-T: prototype for development of anti-tumor vaccines. Curr Oncol Rep. 2011;13(2):112-119.
11. Celis E, et al. Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles. Mol Immunol. 1994;31(18):1423-1430. (Pubitemid 24381799)
12. Wolfel T, et al. Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL). Int J Cancer. 1993;55(2):237-244. (Pubitemid 23296022)
13. Kawakami Y, et al. Identification of theimmunodominant peptides of theMART-1 humanmelanoma antigen recognized by themajority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med. 1994;180(1):347-352. (Pubitemid 24181083)
14. Dudley ME, et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother. 2002;25(3):243-251. (Pubitemid 34533314)
15. Rosenberg SA,Dudley ME.Cancer regression in patientswith metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A. 2004;101(Suppl 2):14639-14645. (Pubitemid 39346736)
16. Hughes MS, et al. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther. 2005;16(4):457-472. (Pubitemid 40647143)
17. Verma B, et al. TCR mimic monoclonal antibodies induce apoptosis of tumor cells via immune effector-independentmechanisms. J Immunol. 2011;186(5):3265-3276.
18. Hawkins OE, et al. Identification of breast cancer peptide epitopes presented by HLA-A*0201. J Proteome Res. 2008;7(4):1445-1457.
19. Verma B, et al. Direct discovery and validation of a peptide/MHC epitope expressed in primary human breast cancer cells using a TCRm monoclonal antibody with profound antitumor properties. Cancer Immunol Immunother. CII, 2010;59(4):563-573.
20. Verma B, et al. TCR mimic monoclonal antibody targets a specific peptide/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models. J Immunol. 2010;184(4):2156-2165.
21. Kim S, et al. Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection. J Immunol. 2010;184(8):4423-4430.
22. Hawkins O, et al. An HLA-presented fragment of macrophagemigration inhibitory factor is a therapeutic target for invasive breast cancer. J Immunol. 2011;186(11):6607-6616.
23. Hunt DF, et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science. 1992;255(5049):1261-1263.
24. Bhattacharya R, et al. A novel vascular targeting strategy for brain-derived endothelial cells using a TCRmimic antibody. J Cellular Physiol. 2010;225(3):664-672.